Abstract:Key PointsTumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a molecule belonging to the tumour necrosis factor (TNF) superfamily. In humans, two TRAIL receptors (TRAIL-R1 and TRAIL-R2) and in mice one receptor (mTRAIL-R) can signal apoptosis upon binding of TRAIL.Induction of apoptosis is enabled through recruitment of the death-inducing signalling complex (DISC). This complex leads to activation of a caspase cascade.TRAIL–TRAIL-R binding can also induce non-apoptotic signalling including via activation of nuclear factor-κB (NF-κB), p38, ERK, SRC and RAC1.Mice deficient in TRAIL or mTRAIL-R are more susceptible to various cancers whereas conditional deletion of mTRAIL-R in Kras- driven cancers ameliorates disease progression. TRAIL–TRAIL-R blockade might therefore be a therapeutic option for patients with KRAS-mutated cancers.TRAIL–TRAIL-R interaction on myeloid-derived suppressor cells in the tumour microenvironment can limit their lifespan and thereby tip the balance towards an antitumour immune environment. Hence, patients with an immunosuppressive cancer microenvironment might benefit from TRAIL-R agonistic therapy.Clinical trials testing an untagged form of recombinant TRAIL, agonistic TRAIL-R1 or TRAIL-R2-specific antibodies or antibody derivatives with higher crosslinking capacity have not led to anticipated therapeutic benefit.Preclinical approaches using therapeutic combinations comprising optimized TRAIL-R agonists and recently discovered powerful apoptosis sensitizers are, however, promising. Therefore, such novel pro-apoptotic combination therapies should be tested in clinical trials.Several drugs, some of which have been approved by the US Food and Drug Administration, induce extrinsic apoptosis through autocrine engagement of the TRAIL–TRAIL-R pathway. Therefore, expression of TRAIL apoptosis pathway components, as well as lack of expression of inhibitors thereof, might be useful for patient selection in clinical trials testing the efficacy of such drugs.

Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling

TRAIL and Cancer Therapy

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies

Developing TRAIL/TRAIL death receptor-based cancer therapies

The multifaceted role of TRAIL signaling in cancer and immunity

TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

Molecular Mechanisms of TRAIL-induced Apoptosis of Cancer Cells

Regulation of anoikis by extrinsic death receptor pathways

Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

Mechanism of TRAIL Induced Tumor Cell Apoptosis and Application of TRAIL Based on Tumor Therapy

Advance Research in Apoptosis Mediating by Death Receptor

TNF-related Apoptosis-Inducing Ligand and Tumor

Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells

Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation

Research and Applicatuon of Death Receptor 5-Mediated Apoptosis

TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

TRAIL Agonists on Clinical Trials for Cancer Therapy: the Promises and the Challenges.

Targeting Micrornas to Modulate TRAIL-induced Apoptosis of Cancer Cells